CHARLOTTESVILLE, VA – June 02, 2026 – The frontier of modern medicine is not a pill; it is a living cell, reprogrammed and redeployed to fight our most intractable diseases. From cancer to genetic disorders, cell and gene therapies represent a paradigm shift in treatment. Yet, behind the...
Daniel J. Weiss, MD, PhD President, ISCT United States Greetings and hope everyone is enjoying summer in the Northern hemisphere and otherwise doing well across the global ISCT family. There continues to be increasing activities in CGT globally, both good and bad. ISCT continues to...
Developed by the ISCT Cold Chain Management and Logistics Working Group and the ISCT Process Development and Manufacturing Committee Introduction Cryopreservation is central to the manufacturing, distribution, and clinical delivery of cell and gene therapy products. Freezing enables...
Patrick Foong, PhD Member, ISCT Ethics of Cell and Gene Therapy (ECGT) Committee Western Sydney University Australia Gabrielle O'Sullivan, PhD, MPH(Hons), BSc Chief Regulatory Officer, ISCT Vice-Chair, Regulatory, ISCT Ethics of Cell and Gene Therapy (ECGT) Committee Royal Prince Alfred...
Fajar Dumadi, BSc International Society for Cell & Gene Therapy (ISCT) Canada Committee for Advanced Therapies (CAT) Agendas for Recent Meetings Agenda of the CAT meeting 15-17 July 2026 https://www.ema.europa.eu/en/documents/agenda/agenda-cat-meeting-15-17-july-2026 en.pdf ...
Jay Tanna, MS, RAC(US) Senior Manager, QA Children's National Hospital United States FDA Highlights Ebola Considerations for HCT/P Establishments Amid New Outbreak In July 2026, the U.S. Food and Drug Administration (FDA) issued a Safety and Availability communication to Human Cells,...
Jessica Sue, BSc, MHSM Co-Senior Editor, ISCT Telegraft Quality Manager Sydney Cord Blood Bank, Sydney Children’s Hospitals Network Australia In 2019, I signed up as an ISCT member with encouragement from my manager, Guy Klamer. Joining the ISCT community has opened the door to...
1 Comment - no search term matches found in comments.
On behalf of the Business Development & Finance Committee The cell and gene therapy (CGT) industry continues to evolve rapidly, with investment activity providing an important window into where investors and biopharma companies see future opportunity. As part of its quarterly market...
Gemma Moir-Meyer, PhD Co-Chair, ISCT ANZ Regional ESP Subcommittee Regional Secretary, ISCT ANZ Region University of Otago New Zealand On behalf of the ISCT Early Stage Professionals (ESP) Community Engagement Working Group How did your journey into cell and gene therapy ...
On Behalf of the Planning Committee for ISCT's Clinical Applications Program for Fellows A fully funded, two-day immersion at the University of Pennsylvania for clinical fellows across the US and Canada. Applications now open, closing July 31, 2026. Cell and gene therapies...